ClinicalTrials.gg
CompletedNCT06039189SPECTREMUpdated May 1, 2026Results posted

Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis

A Phase 3 interventional study of Guselkumab and Placebo in Moderate Plaque Psoriasis, sponsored by Janssen Research & Development, LLC. Completed at 64 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
338
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing guselkumab in Psoriasis — 8 open to participants now, 9 under way, 1 of them phase 3. guselkumab · Psoriasis.

Enrollment
6th of 29
338 · median 120
Started
2023
with 2 others
Phase 3
12 of 29
none open now
Registered
24th of 29
by date
Lead sponsor
9 of 29
Janssen Research & Development, LLC

Among the 29 studies testing guselkumab in Psoriasis, this one is the 6th largest by enrollment, is one of 3 that started in 2023, is one of 12 in phase 3, and was the 24th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

8 of the 29 studies testing guselkumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About guselkumab

guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing guselkumab in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of guselkumab compared to an inactive drug in participants with low body surface area moderate plaque psoriasis and special site involvement.

03

Conditions studied

  • Moderate Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All participants must have a diagnosis of plaque psoriasis (with or without psoriatic arthritis) for at least 6 months before first administration of study intervention
  • All participants must meet the following disease severity criteria at screening and at baseline: (a) Overall Investigator's Global Assessment (IGA) 3 (moderate) plaque psoriasis; (b) Body Surface Area (BSA) 2-15 percent (%) with at least 1 plaque outside of special sites; (c) Involvement of at least 1 special site with at least moderate severity. Qualifying sites include scalp with scalp-specific IGA greater than or equal to (>=) 3, face with facial psoriasis IGA >=3, intertriginous with intertriginous psoriasis IGA >=3, or genital with static physician global assessment of genitalia (sPGA-G) >=3
  • All participants be inadequately controlled with or intolerant of at least 1 prior topical therapy (including, but not limited to, , retinoids, vitamin D, or vitamin D/steroid and retinoid/steroid combinations, tacrolimus, pimecrolimus, anthralin/dithranol, coal tar preparations, tapinarof, roflumilast, etcetera) for the treatment of psoriasis at both screening
  • All participants be a candidate for phototherapy or systemic treatment for psoriasis

Exclusion criteria

Exclusion Criteria:

  • Has a nonplaque form of psoriasis (example, erythrodermic, guttate, or pustular) at screening or randomization
  • Has current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
  • For participants with palmoplantar involvement, confounding diagnoses, including, but not limited, to palmoplantar pustulosis, eczematous dermatitis, contact/irritant dermatitis, acquired keratoderma, etcetera, should be confirmed and excluded
  • Participants will not be eligible if they have ever received prior biologic (or biosimilars of) for the treatment of psoriasis, psoriatic arthritis (PsA), or any other indications that could impact the assessment of psoriasis. Prior biologics (or biosimilars of) may include, but not limited to, tumor necrosis factor (TNF)-inhibitors (for example: adalimumab, etanercept, infliximab, or certolizumab or biosimilars), interleukin (IL)-17 inhibitors (for example: secukinumab, ixekizumab, brodalumab, or bimekizumab), and IL-12/23 inhibitors (for example: ustekinumab), or IL-23 inhibitor (for example: guselkumab, risankizumab or tildrakizumab)
  • Has a history of chronic or recurrent infectious disease, including, but not limited to, chronic renal infection, chronic chest infection (for example, bronchiectasis), recurrent urinary tract infection (recurrent pyelonephritis or chronic non-remitting cystitis), fungal infection (mucocutaneous candidiasis), or open, draining, or infected skin wounds or ulcers
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
338 participants (actual)

Study arms

  • Experimental
    Group 1: Guselkumab

    Participants will receive guselkumab by subcutaneous injection with placebo as needed to maintain the blind.

    Drug: Guselkumab · Drug: Placebo

  • Placebo comparator
    Group 2: Placebo

    Participants will receive placebo by subcutaneous injection then receive guselkumab by subcutaneous injection.

    Drug: Guselkumab · Drug: Placebo

Interventions

  • Guselkumab will be administered as subcutaneous injection.

    Also known as: CNTO1959, Tremfya

  • DrugPlacebo

    Placebo will be administered as subcutaneous injection.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16

    The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 millimeters (mm); 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, greater than (\>) 1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). Higher score indicated more severe disease.

    Time frame: Week 16

Secondary outcomes

  1. Percent Change From Baseline in Body Surface Area (BSA) at Week 16

    Percent change from baseline in BSA at Week 16 was reported. A BSA was commonly used measure of severity of skin disease. It was defined as the percentage of surface area of the body involved with the condition being assessed, (that is, plaque psoriasis). BSA was assessed using hand print method where the surface area of the participant's hand including the palm and all 5 digits was used as a guide to estimate 1 percent (%) BSA. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Baseline (Week 0), Week 16

  2. Percent Change From Baseline in Psoriasis Area Severity Index (PASI) Total Score at Week 16

    Percent change from baseline in PASI total score at Week 16 was reported. PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Baseline (Week 0), Week 16

  3. Percentage of Participants Who Achieved IGA Score of Cleared (0) at Week 16

    The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 mm; 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, greater than (\>) 1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). Higher score indicated more severe disease.

    Time frame: Week 16

  4. Percentage of Participants Who Achieved PASI 90 Response at Week 16

    Percentage of participants who achieved PASI 90 score (greater than or equal to \[\>=\] 90% improvement from baseline in PASI) at Week 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Week 16

  5. Percentage of Participants Who Achieved PASI 100 Response at Week 16

    Percentage of participants who achieved PASI-100 score (100% improvement from baseline in PASI) at Week 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Week 16

  6. Percentage of Participants Who Achieved Scalp Specific (ss)-IGA Score of Absence of Disease (0) or Very Mild Disease (1) at Week 16 Among Randomized Participants With Ss-IGA Score >=3 at Baseline

    The ss-IGA instrument was used to evaluate the disease severity of scalp psoriasis. The lesions were assessed in terms of the clinical signs of redness, thickness, and scaliness which was scored as: absence of disease = 0, very mild disease = 1, mild disease = 2, moderate disease = 3, and severe disease = 4. A higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Week 16

  7. Percentage of Participants Who Achieved Static Physician's Global Assessment of Genitalia (sPGA-G) Score of 0 or 1 at Week 16 Among Randomized Participants With sPGA-G Score >=3 at Baseline

    The sPGA-G was a 6-point scale to assess the severity of genital psoriasis at a given time point. The sPGA-G evaluates erythema, plaque elevation, and scale of genital psoriatic lesions. The severity of genital psoriasis was assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), and very severe (5). Higher score indicates more severity. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Week 16

  8. Percentage of Participants Who Achieved Intertriginous IGA (i-IGA) Score of Clear (0) or Minimal (1) at Week 16 Among Randomized Participants With an i-IGA Score >=3 at Baseline

    The IGA used for the full body assessment was adapted with descriptions of disease features that were more consistent with intertriginous psoriasis presentation. The intertriginous areas assessed included the axillary, sub mammary, abdominal fold, inguinal, and intergluteal cleft/peri-anal region (distinct from genital/perineum involvement). The i-IGA was 5-point scale evaluating the severity of plaque psoriasis in the intertriginous area with scores defined as clear (0), minimal (1), mild (2), moderate (3), and severe (4). A higher score indicated greater disease severity. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Week 16

  9. Percentage of Participants Who Achieved Facial IGA (f-IGA) Score of Clear (0) or Minimal (1) at Week 16 Among Randomized Participants With f-IGA Score >=3 at Baseline

    The standard IGA used for full body evaluation was adapted for assessment of psoriasis on the face only. The f-IGA used a 5-point scale to assess overall facial disease severity, defined as clear (0), minimal (1), mild (2), moderate (3), and severe (4). A higher score indicated more severe facial psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Week 16

  10. Change From Baseline in Psoriasis Symptom and Sign Diary (PSSD) Total Symptom Score at Week 16

    The PSSD was a patient reported outcome (PRO) questionnaire designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. 7-day recall version was used. PSSD was a self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Items were averaged on the weekly symptom score when at least 3 items (\>=50 percentage of 5 items) on these scales were answered. The average value was converted into 0-100 scoring, such that symptom score = average value\*10, where, 0= least severe and 100= most severe. Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Baseline (Week 0), Week 16

  11. Percentage of Participants Who Achieved >=4-Point Improvement From Baseline in PSSD Itch Score at Week 16 Among Participants With a PSSD Itch Score >=4 at Baseline

    PSSD was a PRO questionnaire designed to measure severity of psoriasis symptoms and signs for assessment of treatment benefit. 7-day recall version was used. PSSD was a self-administered PRO instrument that included 11 items covering symptoms(itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. PSSD itch item score over seven days was averaged into a weekly itch score, ranging from 0 to 10 with higher scores indicating severe disease. Baseline was defined as the closest measurement taken prior to or at time of first study drug administration date.

    Time frame: Week 16

  12. Percentage of Participants Who Achieved PSSD Individual Symptom Scale Score=0 at Week 16 Among Participants With a PSSD Symptom Score >0 at Baseline

    The PSSD was a PRO questionnaire designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. 7-day recall version was used. PSSD was a self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Items were averaged on the weekly symptom score when at least 3 items (\>=50 percentage of 5 items) on these scales are answered. The average value was converted into 0-100 scoring, such that symptom score = average value\*10, where, 0= least severe and 100= most severe. Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Week 16

  13. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAE was defined as any event that occurred after the start of initial study agent administration and those AEs that were presented at baseline but worsened in severity after the start of initial study agent administration.

    Time frame: Group 1: Placebo: From Week 0 to Week 16; Group 1: Placebo followed by Guselkumab 100 mg: From Week 16 to Week 56; Group 2: Guselkumab 100 mg: From Week 0 to Week 56

  14. Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs)

    An AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or resulted in congenital anomaly/birth defect. TEAE was defined as any event that occurred after the start of initial study agent administration and those AEs that were presented at baseline but worsened in severity after the start of initial study agent administration.

    Time frame: Group 1: Placebo: From Week 0 to Week 16; Group 1: Placebo followed by Guselkumab 100 mg: From Week 16 to Week 56; Group 2: Guselkumab 100 mg: From Week 0 to Week 56

07

Results

Posted May 1, 2026

Participant flow

Participant flow — Overall Study
MilestoneGroup 1: Placebo Followed by Guselkumab 100 mgGroup 2: Guselkumab 100 mg
Started113225
Participants from placebo who crossed over to guselkumab1040
Completed95208
Not completed1817
Withdrew: Adverse event20
Withdrew: Lack of efficacy31
Withdrew: Lost to follow-up36
Withdrew: Physician decision01
Withdrew: Other22
Withdrew: Withdrawal by subject87

Outcome measures

PrimaryPercentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16

The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 millimeters (mm); 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, greater than (\>) 1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). Higher score indicated more severe disease.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16
Percentage of participantsGroup 1: Placebo Followed by Guselkumab 100 mgGroup 2: Guselkumab 100 mg
Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 1612.474.2
Statistical analysis
  • Group 1: Placebo Followed by Guselkumab 100 mg vs Group 2: Guselkumab 100 mg · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted treatment difference: 61.8 · 95% CI 53.4 to 70.1
SecondaryPercent Change From Baseline in Body Surface Area (BSA) at Week 16

Percent change from baseline in BSA at Week 16 was reported. A BSA was commonly used measure of severity of skin disease. It was defined as the percentage of surface area of the body involved with the condition being assessed, (that is, plaque psoriasis). BSA was assessed using hand print method where the surface area of the participant's hand including the palm and all 5 digits was used as a guide to estimate 1 percent (%) BSA. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Baseline (Week 0), Week 16
Reported as:
Mean · Percent change
Percent Change From Baseline in Body Surface Area (BSA) at Week 16
Percent changeGroup 1: Placebo Followed by Guselkumab 100 mgGroup 2: Guselkumab 100 mg
Percent Change From Baseline in Body Surface Area (BSA) at Week 16-5.6 ± 54.33-80.5 ± 27.78
Statistical analysis
  • Group 1: Placebo Followed by Guselkumab 100 mg vs Group 2: Guselkumab 100 mg · Mixed Model Repeated Measures · p = <0.001 · Least square (ls) mean difference: -74.48 · 95% CI -83.33 to -65.62
SecondaryPercent Change From Baseline in Psoriasis Area Severity Index (PASI) Total Score at Week 16

Percent change from baseline in PASI total score at Week 16 was reported. PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Baseline (Week 0), Week 16
Reported as:
Mean · Percent change
Percent Change From Baseline in Psoriasis Area Severity Index (PASI) Total Score at Week 16
Percent changeGroup 1: Placebo Followed by Guselkumab 100 mgGroup 2: Guselkumab 100 mg
Percent Change From Baseline in Psoriasis Area Severity Index (PASI) Total Score at Week 16-13.6 ± 50.78-82.6 ± 24.24
Statistical analysis
  • Group 1: Placebo Followed by Guselkumab 100 mg vs Group 2: Guselkumab 100 mg · Mixed Model Repeated Measures · p = <0.001 · Ls mean difference: -68.96 · 95% CI -77.06 to -60.87
SecondaryPercentage of Participants Who Achieved IGA Score of Cleared (0) at Week 16

The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 mm; 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, greater than (\>) 1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). Higher score indicated more severe disease.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved IGA Score of Cleared (0) at Week 16
Percentage of participantsGroup 1: Placebo Followed by Guselkumab 100 mgGroup 2: Guselkumab 100 mg
Percentage of Participants Who Achieved IGA Score of Cleared (0) at Week 163.540.4
Statistical analysis
  • Group 1: Placebo Followed by Guselkumab 100 mg vs Group 2: Guselkumab 100 mg · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted treatment difference: 36.9 · 95% CI 29.6 to 44.1
SecondaryPercentage of Participants Who Achieved PASI 90 Response at Week 16

Percentage of participants who achieved PASI 90 score (greater than or equal to \[\>=\] 90% improvement from baseline in PASI) at Week 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved PASI 90 Response at Week 16
Percentage of participantsGroup 1: Placebo Followed by Guselkumab 100 mgGroup 2: Guselkumab 100 mg
Percentage of Participants Who Achieved PASI 90 Response at Week 166.252.9
Statistical analysis
  • Group 1: Placebo Followed by Guselkumab 100 mg vs Group 2: Guselkumab 100 mg · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted treatment difference: 46.6 · 95% CI 38.8 to 54.5
SecondaryPercentage of Participants Who Achieved PASI 100 Response at Week 16

Percentage of participants who achieved PASI-100 score (100% improvement from baseline in PASI) at Week 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved PASI 100 Response at Week 16
Percentage of participantsGroup 1: Placebo Followed by Guselkumab 100 mgGroup 2: Guselkumab 100 mg
Percentage of Participants Who Achieved PASI 100 Response at Week 162.732.4
Statistical analysis
  • Group 1: Placebo Followed by Guselkumab 100 mg vs Group 2: Guselkumab 100 mg · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted treatment difference: 29.7 · 95% CI 23.0 to 36.5
SecondaryPercentage of Participants Who Achieved Scalp Specific (ss)-IGA Score of Absence of Disease (0) or Very Mild Disease (1) at Week 16 Among Randomized Participants With Ss-IGA Score >=3 at Baseline

The ss-IGA instrument was used to evaluate the disease severity of scalp psoriasis. The lesions were assessed in terms of the clinical signs of redness, thickness, and scaliness which was scored as: absence of disease = 0, very mild disease = 1, mild disease = 2, moderate disease = 3, and severe disease = 4. A higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Scalp Specific (ss)-IGA Score of Absence of Disease (0) or Very Mild Disease (1) at Week 16 Among Randomized Participants With Ss-IGA Score >=3 at Baseline
Percentage of participantsGroup 1: Placebo Followed by Guselkumab 100 mgGroup 2: Guselkumab 100 mg
Percentage of Participants Who Achieved Scalp Specific (ss)-IGA Score of Absence of Disease (0) or Very Mild Disease (1) at Week 16 Among Randomized Participants With Ss-IGA Score >=3 at Baseline14.575.0
Statistical analysis
  • Group 1: Placebo Followed by Guselkumab 100 mg vs Group 2: Guselkumab 100 mg · Chi-squared · p = <0.001 · Adjusted treatment difference: 60.5 · 95% CI 50.0 to 71.0
SecondaryPercentage of Participants Who Achieved Static Physician's Global Assessment of Genitalia (sPGA-G) Score of 0 or 1 at Week 16 Among Randomized Participants With sPGA-G Score >=3 at Baseline

The sPGA-G was a 6-point scale to assess the severity of genital psoriasis at a given time point. The sPGA-G evaluates erythema, plaque elevation, and scale of genital psoriatic lesions. The severity of genital psoriasis was assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), and very severe (5). Higher score indicates more severity. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Static Physician's Global Assessment of Genitalia (sPGA-G) Score of 0 or 1 at Week 16 Among Randomized Participants With sPGA-G Score >=3 at Baseline
Percentage of participantsGroup 1: Placebo Followed by Guselkumab 100 mgGroup 2: Guselkumab 100 mg
Percentage of Participants Who Achieved Static Physician's Global Assessment of Genitalia (sPGA-G) Score of 0 or 1 at Week 16 Among Randomized Participants With sPGA-G Score >=3 at Baseline37.578.0
Statistical analysis
  • Group 1: Placebo Followed by Guselkumab 100 mg vs Group 2: Guselkumab 100 mg · Chi-squared · p = <0.001 · Adjusted treatment difference: 40.5 · 95% CI 23.1 to 58.0
SecondaryPercentage of Participants Who Achieved Intertriginous IGA (i-IGA) Score of Clear (0) or Minimal (1) at Week 16 Among Randomized Participants With an i-IGA Score >=3 at Baseline

The IGA used for the full body assessment was adapted with descriptions of disease features that were more consistent with intertriginous psoriasis presentation. The intertriginous areas assessed included the axillary, sub mammary, abdominal fold, inguinal, and intergluteal cleft/peri-anal region (distinct from genital/perineum involvement). The i-IGA was 5-point scale evaluating the severity of plaque psoriasis in the intertriginous area with scores defined as clear (0), minimal (1), mild (2), moderate (3), and severe (4). A higher score indicated greater disease severity. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Intertriginous IGA (i-IGA) Score of Clear (0) or Minimal (1) at Week 16 Among Randomized Participants With an i-IGA Score >=3 at Baseline
Percentage of participantsGroup 1: Placebo Followed by Guselkumab 100 mgGroup 2: Guselkumab 100 mg
Percentage of Participants Who Achieved Intertriginous IGA (i-IGA) Score of Clear (0) or Minimal (1) at Week 16 Among Randomized Participants With an i-IGA Score >=3 at Baseline28.886.5
Statistical analysis
  • Group 1: Placebo Followed by Guselkumab 100 mg vs Group 2: Guselkumab 100 mg · Chi-squared · p = <0.001 · Adjusted treatment difference: 57.6 · 95% CI 43.8 to 71.5
SecondaryPercentage of Participants Who Achieved Facial IGA (f-IGA) Score of Clear (0) or Minimal (1) at Week 16 Among Randomized Participants With f-IGA Score >=3 at Baseline

The standard IGA used for full body evaluation was adapted for assessment of psoriasis on the face only. The f-IGA used a 5-point scale to assess overall facial disease severity, defined as clear (0), minimal (1), mild (2), moderate (3), and severe (4). A higher score indicated more severe facial psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Facial IGA (f-IGA) Score of Clear (0) or Minimal (1) at Week 16 Among Randomized Participants With f-IGA Score >=3 at Baseline
Percentage of participantsGroup 1: Placebo Followed by Guselkumab 100 mgGroup 2: Guselkumab 100 mg
Percentage of Participants Who Achieved Facial IGA (f-IGA) Score of Clear (0) or Minimal (1) at Week 16 Among Randomized Participants With f-IGA Score >=3 at Baseline28.687.8
Statistical analysis
  • Group 1: Placebo Followed by Guselkumab 100 mg vs Group 2: Guselkumab 100 mg · Chi-squared · p = <0.001 · Adjusted treatment difference: 59.2 · 95% CI 44.0 to 74.5
SecondaryChange From Baseline in Psoriasis Symptom and Sign Diary (PSSD) Total Symptom Score at Week 16

The PSSD was a patient reported outcome (PRO) questionnaire designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. 7-day recall version was used. PSSD was a self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Items were averaged on the weekly symptom score when at least 3 items (\>=50 percentage of 5 items) on these scales were answered. The average value was converted into 0-100 scoring, such that symptom score = average value\*10, where, 0= least severe and 100= most severe. Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Baseline (Week 0), Week 16
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Psoriasis Symptom and Sign Diary (PSSD) Total Symptom Score at Week 16
Units on a scaleGroup 1: Placebo Followed by Guselkumab 100 mgGroup 2: Guselkumab 100 mg
Change From Baseline in Psoriasis Symptom and Sign Diary (PSSD) Total Symptom Score at Week 160.37 (-3.92 to 4.67)-36.08 (-39.11 to -33.06)
Statistical analysis
  • Group 1: Placebo Followed by Guselkumab 100 mg vs Group 2: Guselkumab 100 mg · Mixed Model Repeated Measures · p = <0.001 · Ls mean difference: -36.45 · 95% CI -41.71 to -31.20
SecondaryPercentage of Participants Who Achieved >=4-Point Improvement From Baseline in PSSD Itch Score at Week 16 Among Participants With a PSSD Itch Score >=4 at Baseline

PSSD was a PRO questionnaire designed to measure severity of psoriasis symptoms and signs for assessment of treatment benefit. 7-day recall version was used. PSSD was a self-administered PRO instrument that included 11 items covering symptoms(itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. PSSD itch item score over seven days was averaged into a weekly itch score, ranging from 0 to 10 with higher scores indicating severe disease. Baseline was defined as the closest measurement taken prior to or at time of first study drug administration date.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved >=4-Point Improvement From Baseline in PSSD Itch Score at Week 16 Among Participants With a PSSD Itch Score >=4 at Baseline
Percentage of participantsGroup 1: Placebo Followed by Guselkumab 100 mgGroup 2: Guselkumab 100 mg
Percentage of Participants Who Achieved >=4-Point Improvement From Baseline in PSSD Itch Score at Week 16 Among Participants With a PSSD Itch Score >=4 at Baseline12.562.7
Statistical analysis
  • Group 1: Placebo Followed by Guselkumab 100 mg vs Group 2: Guselkumab 100 mg · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted treatment difference: 50.3 · 95% CI 41.2 to 59.4
SecondaryPercentage of Participants Who Achieved PSSD Individual Symptom Scale Score=0 at Week 16 Among Participants With a PSSD Symptom Score >0 at Baseline

The PSSD was a PRO questionnaire designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. 7-day recall version was used. PSSD was a self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Items were averaged on the weekly symptom score when at least 3 items (\>=50 percentage of 5 items) on these scales are answered. The average value was converted into 0-100 scoring, such that symptom score = average value\*10, where, 0= least severe and 100= most severe. Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved PSSD Individual Symptom Scale Score=0 at Week 16 Among Participants With a PSSD Symptom Score >0 at Baseline
Percentage of participantsGroup 1: Placebo Followed by Guselkumab 100 mgGroup 2: Guselkumab 100 mg
Percentage of Participants Who Achieved PSSD Individual Symptom Scale Score=0 at Week 16 Among Participants With a PSSD Symptom Score >0 at Baseline2.721.9
Statistical analysis
  • Group 1: Placebo Followed by Guselkumab 100 mg vs Group 2: Guselkumab 100 mg · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted treatment difference: 19.2 · 95% CI 13.1 to 25.4
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAE was defined as any event that occurred after the start of initial study agent administration and those AEs that were presented at baseline but worsened in severity after the start of initial study agent administration.

Time frame:
Group 1: Placebo: From Week 0 to Week 16; Group 1: Placebo followed by Guselkumab 100 mg: From Week 16 to Week 56; Group 2: Guselkumab 100 mg: From Week 0 to Week 56
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsGroup 1: PlaceboGroup 1: Placebo Followed by Guselkumab 100 mgGroup 2: Guselkumab 100 mg
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)4556138
SecondaryNumber of Participants With Treatment-Emergent Serious Adverse Events (TESAEs)

An AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or resulted in congenital anomaly/birth defect. TEAE was defined as any event that occurred after the start of initial study agent administration and those AEs that were presented at baseline but worsened in severity after the start of initial study agent administration.

Time frame:
Group 1: Placebo: From Week 0 to Week 16; Group 1: Placebo followed by Guselkumab 100 mg: From Week 16 to Week 56; Group 2: Guselkumab 100 mg: From Week 0 to Week 56
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs)
ParticipantsGroup 1: PlaceboGroup 1: Placebo Followed by Guselkumab 100 mgGroup 2: Guselkumab 100 mg
Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs)1212

Adverse events

Collected over Group 1: Placebo: From Week 0 to Week 16; Group 1: Placebo followed by Guselkumab 100 mg: From Week 16 to Week 56; Group 2: Guselkumab 100 mg: From Week 0 to Week 56. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: Placebo0/113 (0%)1/113 (0.9%)12/113 (10.6%)
Group 1: Placebo Followed by Guselkumab 100 mg0/104 (0%)2/104 (1.9%)27/104 (26%)
Group 2: Guselkumab 100 mg0/225 (0%)12/225 (5.3%)50/225 (22.2%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventGroup 1: PlaceboGroup 1: Placebo Followed by Guselkumab 100 mgGroup 2: Guselkumab 100 mg
CholelithiasisHepatobiliary disorders0/1131/1040/225
AppendicitisInfections and infestations0/1131/1040/225
PneumoniaInfections and infestations1/1130/1040/225
Angina UnstableCardiac disorders0/1130/1041/225
Cardiac Failure CongestiveCardiac disorders0/1130/1041/225
Coronary Artery OcclusionCardiac disorders0/1130/1041/225
Myocardial InfarctionCardiac disorders0/1130/1041/225
PancreatitisGastrointestinal disorders0/1130/1041/225
VomitingGastrointestinal disorders0/1130/1041/225
Cholecystitis AcuteHepatobiliary disorders0/1130/1041/225
Most frequent other events
Most frequent other events
EventGroup 1: PlaceboGroup 1: Placebo Followed by Guselkumab 100 mgGroup 2: Guselkumab 100 mg
Upper Respiratory Tract InfectionInfections and infestations3/11315/10434/225
Covid-19Infections and infestations1/1138/10410/225
NasopharyngitisInfections and infestations8/1135/10415/225

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Group 1: Placebo Followed by Guselkumab 100 mgGroup 2: Guselkumab 100 mgTotal
<=18 years000
Between 18 and 65 years97195292
>=65 years163046
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: Placebo Followed by Guselkumab 100 mgGroup 2: Guselkumab 100 mgTotal
Female56109165
Male57116173
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1: Placebo Followed by Guselkumab 100 mgGroup 2: Guselkumab 100 mgTotal
Hispanic or Latino203252
Not Hispanic or Latino93193286
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Group 1: Placebo Followed by Guselkumab 100 mgGroup 2: Guselkumab 100 mgTotal
American Indian or Alaska Native235
Asian71623
Black or African American31013
Native Hawaiian or Other Pacific Islander022
White83166249
More than one race6915
Unknown or Not Reported000
Other121931
Age, Continuous
Age, Continuous(Years)Group 1: Placebo Followed by Guselkumab 100 mgGroup 2: Guselkumab 100 mgTotal
Mean44.5 ± 14.9447 ± 14.7446.2 ± 14.83
Region of Enrollment
Region of Enrollment(Participants)Group 1: Placebo Followed by Guselkumab 100 mgGroup 2: Guselkumab 100 mgTotal
CANADA67140207
UNITED STATES4685131
08

Study locations

64 sites
  • Total Dermatology
    Birmingham, Alabama 35203, United States
  • Cahaba Research Inc
    Birmingham, Alabama 35244, United States
  • California Dermatology & Clinical Research Institute
    Encinitas, California 92024, United States
  • First OC Dermatology
    Fountain Valley, California 92708, United States
  • Practice Wang
    Riverside, California 92505, United States
  • Therapeutics Clinical Research
    San Diego, California 92123, United States
  • Rehlen, Bartlow, Goodman and Baron Dermatology Group
    Santa Ana, California 92701, United States
  • Clinical Science Institute
    Santa Monica, California 90404, United States
  • University of Conn Health Center
    Farmington, Connecticut 06030, United States
  • TrueBlue Clinical Research
    Brandon, Florida 33511, United States
  • Florida Academic Dermatology Centers
    Coral Gables, Florida 33134, United States
  • Revival Research
    Doral, Florida 33122, United States
  • Glick Research Institute
    Margate, Florida 33063, United States
  • Miami VA Healthcare System
    Miami, Florida 33124, United States
  • Tory P Sullivan M D PA
    North Miami Beach, Florida 33162, United States
  • Atlanta Biomedical Clinical Research
    Atlanta, Georgia 303331, United States
  • Kindred Hair and Skin Center
    Columbia, Maryland 21045, United States
  • DermAssociates, PC
    Rockville, Maryland 20850, United States
  • Lawrence J Green MD LLC
    Rockville, Maryland 20850, United States
  • Metro Boston Clinical Partners
    Brighton, Massachusetts 02135, United States
  • DermCare, LLC
    Quincy, Massachusetts 02169, United States
  • Henry Ford Medical Center
    West Bloomfield, Michigan 48322, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10003, United States
  • Markowitz Medical OptiSkin
    New York, New York 10128, United States
  • Accellacare Research of Cary
    Cary, North Carolina 27511, United States
  • Darst Dermatology
    Charlotte, North Carolina 28277, United States
  • Piedmont Plastic Surgery and Dermatology
    Huntersville, North Carolina 28078, United States
  • Bexley dermatology research
    Bexley, Ohio 43209, United States
  • Remington Davis Inc
    Columbus, Ohio 43215, United States
  • Apex Dermatology Mayfield Heights
    Mayfield Heights, Ohio 44124, United States
  • Dermatology and Laser Center of Charleston
    Charleston, South Carolina 29414, United States
  • Palmetto Clinical Trial Services, LLC
    Fountain Inn, South Carolina 29644, United States
  • Nashville Skin: Comprehensive Dermatology Center
    Nashville, Tennessee 37212, United States
  • Tennessee Clinical Research Center
    Nashville, Tennessee 37215, United States
  • Arlington Center for Dermatology
    Arlington, Texas 76011, United States
  • Bellair Dermatology
    Bellaire, Texas 77401, United States
  • Modern Research Associates PLLC
    Dallas, Texas 75231, United States
  • Bare Dermatology
    Dallas, Texas 75235, United States
  • Menter Dermatology Research Institute
    Dallas, Texas 75246, United States
  • Center for Clinical Studies
    Houston, Texas 77004, United States
  • Suzanne Bruce and Associates - The Center for Skin Research
    Houston, Texas 77056-4132, United States
  • Texas Dermatology and Laser Specialists
    San Antonio, Texas 78218, United States
  • Progressive Clinical Research
    San Antonio, Texas 78229, United States
  • Acclaim Dermatology
    Sugar Land, Texas 77479, United States
  • Frontier Derm Partners CRO, LLC
    Mill Creek, Washington 98102, United States
  • Beacon Dermatology
    Calgary, Alberta T3E 0B2, Canada
  • Rejuvenation Dermatology Clinic Edmonton Downtown
    Edmonton, Alberta T5J 3S9, Canada
  • Dr. Chih ho Hong Medical
    Surrey, British Columbia V3R 6A7, Canada
  • Enverus Medical
    Surrey, British Columbia V3V 0C6, Canada
  • Winnipeg Clinic
    Winnipeg, Manitoba R3C 0N2, Canada
  • Wiseman Dermatology Research Inc.
    Winnipeg, Manitoba R3M 3Z4, Canada
  • Brunswick Dermatology Center
    Fredericton, New Brunswick E3B 1G9, Canada
  • CCA Medical Research Corporation
    Ajax, Ontario L1S7K8, Canada
  • SimcoDerm Medical and Surgical Dermatology Centre
    Barrie, Ontario L4M 7G1, Canada
  • Dermatrials Research
    Hamilton, Ontario L8N 1Y2, Canada
  • Dr Wei Jing Loo Medicine Professional Corporation
    London, Ontario N6H 5L5, Canada
  • North York Research Inc
    North York, Ontario M2M 4J5, Canada
  • JRB Research Inc
    Ottawa, Ontario K1H 7X3, Canada
  • Canadian Dermatology Center
    Toronto, Ontario M3B 0A7, Canada
  • Toronto Research Centre
    Toronto, Ontario M3H 5Y8, Canada
  • FACET Dermatology
    Toronto, Ontario M4E 2Y9, Canada
  • Research Toronto
    Toronto, Ontario M4W 2N2, Canada
  • K. Papp Clinical Research Inc.
    Waterloo, Ontario N2J 1C4, Canada
  • The Centre de recherche Saint-Louis
    Québec, Quebec G1W 4R4, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Apr 2025, 19 months.

Results were first posted in May 2026, 1 year after primary completion.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 19 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2023
First posted
Sep 15, 2023
StartActual
Aug 24, 2023
Primary completionActual
Apr 14, 2025
CompletionActual
Apr 14, 2025
Results first posted
May 1, 2026
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06039189
Responsible party
Sponsor
First posted
Sep 15, 2023
Start date
Aug 24, 2023
Primary completion
Apr 14, 2025
Completion
Apr 14, 2025
Results posted
May 1, 2026
Last update
May 1, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Guselkumab

Start the discussion